Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F12%3A00060678" target="_blank" >RIV/00216224:14110/12:00060678 - isvavai.cz</a>

Alternative codes found

RIV/65269705:_____/12:#0001603

Result on the web

<a href="http://dx.doi.org/10.5301/ejo.5000166" target="_blank" >http://dx.doi.org/10.5301/ejo.5000166</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5301/ejo.5000166" target="_blank" >10.5301/ejo.5000166</a>

Result language

angličtina

Original language name

Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II

Original language description

To investigate efficacy of intravitreal injection of pegaptanib and laser photocoagulation for treatment of stage 3+ retinopathy of prematurity (ROP) affecting zone I and posterior zone II, and to compare the results in terms of regression, development of peripheral retinal vessels, and final structural outcome with conventional laser photocoagulation or combined with cryotherapy. Methods. In a prospective comparative study, 152 eyes with zone I, II posterior ROP 3+ (76 premature rabies), from 2009 to 2011, were included. Patients were randomly assigned to receive intravitreal pegaptanib (Macugen 0.3 mg = 0.02 mL, Pfizer) with conventional diode laser photocoagulation in group 1 (68 eyes of 34 infants) or only laser therapy combined with cryotherapy ingroup 2 (84 eyes of 42 infants), bilaterally. The primary outcome of treatment success was defined as absence of recurrence of stage 3+ ROP. The mean follow-up after treatment was 19.3 months in group 1 and 21.5 months in group 2. Result

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FF - ENT (ie. ear, nose, throat), ophthalmology, dentistry

OECD FORD branch

—

Project

<a href="/en/project/NS9892" target="_blank" >NS9892: Intravitreal injection of selective inhibitor of vascular endothelial growth factor (anti -VEGF), pegaptanib sodium, in the treatment of retinopathy of prematurity</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European Journal of Ophthalmology

ISSN

1120-6721

e-ISSN

—

Volume of the periodical

22

Issue of the periodical within the volume

5

Country of publishing house

IT - ITALY

Number of pages

8

Pages from-to

687-694

UT code for WoS article

000310177100002

EID of the result in the Scopus database

—